Meghan T. Logun

Dec 9, 2024 | cell.com | Meghan T. Logun |Xin Wang |Yusha Sun |Stephen J. Bagley |Nannan Li |Arati Desai | +9 more

Keywordsglioblastomapatient-derived tumor organoidex vivoCAR-T cell therapyreal-time correlativeclinical trialorganoidcytokineGet full text accessLog in, subscribe or purchase for full access. References1. Drost, J. ∙ Clevers, H. Organoids in cancer researchNat. Rev. Cancer. 2018; 18:407-4182. Jiang, X. ∙ Oyang, L. ∙ Peng, Q. ... Organoids: opportunities and challenges of cancer therapyFront. Cell Dev. Biol. 2023; 11, 12325283. Wang, X. ∙ Sun, Y. ∙ Zhang, D.Y. ...

Oct 4, 2024 | biorxiv.org | Meghan T. Logun |Xin Wang |Yusha Sun |Stephen J. Bagley

AbstractPatient-derived tumor organoids have been leveraged for disease modeling and preclinical studies, but rarely applied in real-time to aid with interpretation of patient treatment responses in clinics. We recently demonstrated early efficacy signals in a first-in-human, phase 1 study of dual-targeting chimeric antigen receptor T cells (EGFR-IL13Rα2 CAR-T cells) in patients with recurrent glioblastoma.

May 11, 2024 | insights.bio | Meghan T. Logun

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format. Glioblastoma is an aggressive form of brain cancer with no effective treatments currently available. Consequently, new therapeutic approaches, such as immunotherapies, are urgently needed to improve patient outcomes. While CAR-T cell therapies have shown great promise against hematological cancers, their success in solid tumors has been limited.

Apr 23, 2024 | nature.com | Katherine Mueller |Andy Chen |Yingshi Chen |Bence Daniel |Jose Arias-Umana |Alice Wang | +10 more

Correction to: Nature https://doi.org/10.1038/s41586-024-07300-8 Published online 10 April 2024In the version of the article initially published, in the black violin plots in Fig. 5a, a dashed line was used to represent the mean and dotted lines for quartiles. This has now been corrected to a solid line for the mean and dashed lines for the quartiles in the HTML and PDF versions of the article.

Apr 10, 2024 | nature.com | Katherine Mueller |Andy Chen |Yingshi Chen |Bence Daniel |Jose Arias-Umana |Alice Wang | +10 more

AbstractA major limitation of chimeric antigen receptor (CAR) T cell therapies is the poor persistence of these cells in vivo1. The expression of memory-associated genes in CAR T cells is linked to their long-term persistence in patients and clinical efficacy2,3,4,5,6, suggesting that memory programs may underpin durable CAR T cell function. Here we show that the transcription factor FOXO1 is responsible for promoting memory and restraining exhaustion in human CAR T cells.